Recent studies with biological therapy in psoriatic arthritis (PsA) have highlighted the need for validated and widely accepted assessment tools and outcome measures for this disease. A Delphi process was established through the CASPAR group where domains for assessment of PsA in clinical trials, longitudinal studies, and rehabilitation were identified. Although the process reduced the list of possible domains to approximately 12, it was not able to detect those that would be most important. Moreover, skin assessment was left out. A further study through the GRAPPA group subsequently identified the following domains: inflammation (peripheral joints, axial skeleton, physician global assessment), other features (dactylitis, enthesitis), skin and nails, imaging, biomarkers, and patient derived indices (pain, quality of life, itch, function), as important in the assessment of patients with PsA. These domains require further refining, and instruments to measure the items need to be developed. [References: 2]
ContributorsGladman, D. D.
Disease Category: Rheumatology
Disease Name: Psoriatic arthritis
Age Range: Unknown
Sex: Either
Nature of Intervention: Not specified
- Clinical experts
- Consumers (patients)
- Recommendations for outcome measures (measurement/how)
- COS for clinical trials or clinical research
- COS for practice
- Semi structured discussion
Semi structured discussion: meeting